|
|
||||||||



* Julius L. Chambers Biomedical/Biotechnology Research Institute and Department of Biology, North Carolina Central University, Durham, NC 27707;
Department of Biochemistry, Meharry Medical College, Nashville, TN 37208; and
James Graham Brown Cancer Center and Department of Microbiology and Immunology, University of Louisville Health Sciences Center, Louisville, KY 40202
| Abstract |
|---|
|
|
|---|
i3 (PAFR-G
i3) or G
q (PAFR-G
q) at the C terminus of PAFR. Rat basophilic leukemia cell line (RBL-2H3) stably expressing wild-type PAFR, PAFR-G
i3, or PAFR-G
q was generated and characterized. All receptor variants bound PAF with similar affinities to mediate G-protein activation, intracellular Ca2+ mobilization, phosphoinositide (PI) hydrolysis, and secretion of
-hexosaminidase. PAFR-G
i3 and PAFR-G
q mediated greater GTPase activity in isolated membranes than PAFR but lower PI hydrolysis and secretion in whole cells. PAFR and PAFR-G
i3, but not PAFR-G
q, mediated chemotaxis to PAF. All three receptors underwent phosphorylation and desensitization upon exposure to PAF but only PAFR translocated
arrestin to the cell membrane and internalized. In RBL-2H3 cells coexpressing the PAFRs along with CXCR1, IL-8 (CXCL8) cross-desensitized Ca2+ mobilization to PAF by all the receptors but only PAFR-G
i3 activation cross-inhibited the response of CXCR1 to CXCL8. Altogether, the data indicate that Gi exclusively mediates chemotactic and cross-regulatory signals of the PAFR, but both Gi and Gq activate PI hydrolysis and exocytosis by this receptor. Because chemotaxis and cross-desensitization are exclusively mediated by Gi, the data suggest that differential activation of both Gi and Gq by PAFR likely mediate specific as well as redundant signaling pathways. | Introduction |
|---|
|
|
|---|
PAF is produced by a variety of cells (i.e., neutrophils, macrophages, and B cells), and may mediate physiological as well as pathological conditions such as allergic inflammation, anaphylaxis, and asthma (11, 12, 13). Although most chemoattractant receptors couple to a pertussis toxin (Ptx)-sensitive G protein, (predominantly Gi), to activate PLC
, PAFR couples to both Ptx-sensitive and Ptx-insensitive G proteins to mediate cellular responses (14, 15, 16, 17, 18, 19). Reconstitution studies in COS-7 cells demonstrated that PAFR can couple to G
q, G
11, or G
16 to activate PLC
and mediate phosphoinositide (PI) hydrolysis (16). However, in vascular endothelial cells, PAFR was shown to couple specifically to G
q to activate PLC
3 (20). In RBL-2H3 cells that predominantly express PLC
3, we have shown that PAFR-mediated intracellular Ca2+ mobilization was resistant to Ptx whereas secretion and PI hydrolysis were markedly attenuated (21, 22). Responses to PAFR were susceptible to cross-regulation by the peptide chemoattractant receptors formylpeptide receptor (FR), C5aR, and CXCR1 but not vice versa (23). However, a C terminus-deleted mutant of PAFR, deficient in receptor phosphorylation, induced greater G protein activation and cross-desensitized cellular responses to both FR and C5aR (23). In the present work, we sought to determine the precise role of Gi and Gq in PAFR-mediated cellular activation and regulation. For that purpose, PAFR was modified to express either G
i3 (PAFR-G
i3) or G
q (PAFR- G
q) at the C terminus and was stably expressed in the rat basophilic leukemia cell line (RBL-2H3). The ability of the fusion receptors to mediate cell motility, cytotoxicity, and to activate regulatory and cross-regulatory pathways was investigated. The data herein indicate that PAFR uses Gi exclusively to mediate cell motility and cross-regulatory signals, but both Gi and Gq, to mediate secretory activities. Thus, chemoattractant receptors may couple to different G proteins to activate redundant as well as specific pathways.
| Materials and Methods |
|---|
|
|
|---|
[32P]Orthophosphate (85009120 Ci/mM), myo[2-[3H]inositol (24.4 Ci/mM), [3H]WEB 2086 (10.5 Ci/mM), [
-32P]GTP (6000 Ci/mM), and 125I-labeled IL-8 were purchased from PerkinElmer. IL-8 (monocyte derived) was purchased from PeproTech. Geneticin (G418) and all tissue culture reagents were purchased from Invitrogen Life Technologies. Hemagglutinin (HA) mAb, protein G-agarose, and protease inhibitors were from Boehringer Mannheim. Indo-1 acetoxymethyl ester and pluronic acid were from Molecular Probes. PAF, GDP, GTP, and ATP were purchased from Sigma-Aldrich. ERK and phospho-ERK Abs were obtained from Cell Signaling. G
i3 and G
q Abs were purchased from Santa Cruz Biotechnology. pcDNA 3.1 containing human G
q and G
i3 were obtained from the Guthrie cDNA Resource Center. cDNA encoding the GFP-tagged
arrestin-1 (
arr) was a gift from Dr. M. G. Caron (Duke University, Durham, NC). All other reagents were obtained from commercial sources.
Construction of epitope-tagged PAFR and PAFR fusion receptors
Nucleotides encoding a 9-aa HA-epitope sequence (YPYDVPDYA) were inserted between the NH2-terminal initiator methionine and the second amino acid of human PAFR by PCR as previously described (21). To generate the fusion receptors, the HA-PAFR cDNA was altered by adding a HindIII site on the 5' end and replacing the stop codon with a triple alanine sequence followed by a KpnI restriction site at the 3' end. The open reading frame of the receptor cDNA was amplified by PCR using two specific primers: 5'-ACG TAC AAG CTT ATG TAC CCA TAC GAC GTC CCA GAC TAC GCT GAG CCA CAT GAC TCC TCC CAC ATG-3' forward and 5'-TCG ATC GGT ACC TGC TGC TGC TGC CGC ATT TTT GAG GGA ATT GCC AGG GAT CTG-3' reverse. The resulting PCR product as well as the pcDNA-G
q and pcDNA-G
i3 vectors which contain a HindIII-KpnI site at the 5' end of the G
cDNAs were digested with HindIII and KpnI and then ligated. All receptor G protein fusion clones were sequenced to confirm the intended fusion constructs and lack of secondary mutations.
Cell culture and transfection
RBL-2H3 cells were maintained as monolayer cultures in DMEM supplemented with 15% FBS, 2 mM glutamine, penicillin (100 U/ml), and streptomycin (100 mg/ml) (19, 24). These cells (1 x 107 cells) were transfected by electroporation with pcDNA3 containing the receptor cDNAs (20 µg). Geneticin-resistant cells were selected by subculturing the transfected cells in growth medium supplemented with geneticin (1 mg/ml) and cell surface expression of the receptors was monitored by FACS analysis as described previously (21). Double-transfectant RBL-2H3 cells expressing CXCR1 along with PAFR (PAFR-CXCR1) or the fusion receptors (PAFR-G
i3-CXCR1 or PAFR-G
q-CXCR1) were generated as described previously (23).
Radioligand-binding assays
RBL-2H3 cells were subcultured overnight in 24-well plates (0.5 x 106 cells/well) in growth medium. Cells were placed on ice, washed three times with ice-cold PBS containing 10 mg/ml BSA, and incubated for 24 h in DMEM (250 µl) containing the radiolabeled WEB or PAF (0.1 nM). Reactions were stopped with 1 ml of ice-cold PBS, and cells were washed five times. Cells were then solubilized with radioimmunoprecipitation assay buffer (200 µl) and dried under vacuum, and bound radioactivity was counted. Nonspecific radioactivity bound was determined in the presence of 500 nM unlabeled ligand (21).
Western blot analysis
RBL-2H3 cells (5 x 106) expressing the receptors were washed three times with ice-cold PBS, lysed with radioimmunoprecipitation assay, and immunoprecipitated with HA Ab as described previously (25). The immunoprecipitates were resolved in 10% SDS-PAGE, transferred to a nitrocellulose membrane, and probed with Abs against either G
i3 or G
q. Detection was conducted with HRP-conjugated sheep anti-mouse Ab and ECL. For ERK activity, membranes were prepared and assayed for protein concentration as described previously (25). Membrane proteins (
50 µg) were resolved in 10% SDS-PAGE, transferred to a nitrocellulose membrane, and probed with Abs against either ERK 1/2 or phospho-ERK 1/2 (26).
Calcium measurement
Cells (5 x 106) were removed, washed with HEPES-buffered HBSS, and loaded with 1 mM Indo I-AM in the presence of 1 mM pluronic acid for 30 min at room temperature. Then the cells were washed and resuspended in 1.5 ml of buffer. Intracellular calcium increase in the presence of different ligands at the indicated doses was measured as described (27).
Phosphoinositide hydrolysis and secretion of
-hexosaminidase
RBL-2H3 cells were subcultured overnight in 96-well culture plates (50,000 cells/well) in inositol-free medium supplemented with 10% dialyzed FBS and 1 µCi/ml [3H]inositol. Then cells were washed with HEPES-buffered HBSS containing 100 mM LiCl and 0.1% BSA and incubated in the same buffer with and without stimulants. Reactions were stopped by adding 200 ml of chloroform:methanol:4 N HCl (100:200:2). The generation of inositol phosphates was determined as reported (21, 25). For secretion of
-hexosaminidase, cells were subcultured as above, treated with and without agonist, and
-hexosaminidase release in cell lysates was assessed as previously reported (21, 27).
GTPase activity
Cells were treated with appropriate concentrations of stimulants and membranes were prepared as already described (21). GTPase activity, using 10 µg of membrane preparations, was conducted as described previously (21).
Chemotaxis
RBL-2H3 cells stably expressing PAFR and fusion receptor were incubated with calcein AM ionophore for 30 min (28). Cells were resuspended (1.0 x 105/20 µl) in RPMI 1640 without phenol red. Different concentrations of PAF were loaded in a neuroprobe 96-well plate. The cells were added to the top of the filter and incubated for 34 h at 37°C. After incubation, the top of the filter was washed five times with medium and fluorescence intensity of the bottom well plate was measured in a PerkinElmer fluorescence microplate reader.
Phosphorylation of the epitope-tagged receptors
Receptor phosphorylation was performed as described previously (21, 26). Briefly, RBL-2H3 cells (5 x 106) expressing the receptors were subcultured overnight in 60-mm tissue culture dishes. The following day, the cells were rinsed twice with 5 ml of phosphate-free DMEM and incubated in the same medium supplemented with [32P]orthophosphate (150 µCi/dish) for 90 min to metabolically label the intracellular ATP pool. Then labeled cells were stimulated with or without PAF (100 nM) or PMA (100 nM) for 5 min at 37°C. The phosphorylated receptors were immunoprecipitated with the HA Ab, analyzed by SDS electrophoresis, and visualized by autoradiography.
Fluorescence microscopy studies
RBL cells stably expressing PAFR or PAFR-G
i3 or PAFR-G
q were transfected with
arr-GFP by electroporation and grown for 24 h and replated on glass bottom dishes (thickness of glass is 0.17 mm) and allowed to adhere for 1 h at 37°C. The cells were washed with RPMI 1640 medium without phenol red and observed using oil immersion x60 objective lens. The fluorescence images were collected with the TE-FM Epi-Fluorescence system attached to the Nikon Inverted Microscope Eclipse TE300. All images were captured by the cool snap HQ digital B/W CCD (Roper Scientific) camera. A Lamda 10-2 optical filter changer (Sutter Instrument) was used to capture images of
arr-GFP (GFP, FITC exciter (492 nm), and emitter GRNYFP (535 ± 15 nm); Chroma Technology). All the data obtained was analyzed on Metamorph 4.6r5 software (29). All images shown are representative of at least six separate cells from at least three separate experiments.
Receptor internalization
For flow cytometric analysis, cells were detached by versene treatment, washed with PBS, resuspended in the same medium (15 x 106 cells) and treated with PAF (100 nM) for 60 min at 37°C. Cells were washed three times with ice-cold PBS and incubated with HA Ab (1 µg/ml) in a total volume of 400 µl of PBS for 60 min at 4°C. The cells were then washed and incubated with fluorescein (FITC)-anti-mouse IgG for another 60 min at 4°C. Cells were then washed and analyzed for cell surface expression of the receptor on a BD Biosciences FACScan cytometer (30).
| Results |
|---|
|
|
|---|
i3 and PAFR-G
q in RBL-2H3 cells
To determine the role of Gi and Gq in PAFR-mediated leukocyte functions, two fusion receptors, PAFR-G
i3 (PAFR expressing G
i3 at the C terminus) and PAFR-G
q (PAFR expressing G
q at the C terminus), were constructed and stably expressed in RBL-2H3 cells. Expression of the receptors were confirmed by FACS analysis using the HA mAb, which specifically binds the 9-aa HA epitope-tag expressed at N-terminal of the receptor (Fig. 1A). Expression of the G
linked at the C terminus (C-tail) of the receptors was confirmed by Western blotting. Cell lysates from PAFR-G
q, PAFR-G
i3, and PAFR were immunoprecipitated with HA and immunoblotted with anti-Gi3 (Fig. 1B, left panel) or anti-G
q (Fig. 1B, right panel) specific Abs. As shown in Fig. 1B (left panel, lane 2), anti- G
i3 Ab recognized a specific band at
80 kDa which corresponds to PAFR-G
i3 fusion receptor. The anti-G
q Ab also recognized a specific band slightly above 80 kDa (Fig. 1B, right panel, lane 1) which represents the PAFR-G
q fusion receptor.
|
i3 (Kd: 1.48 ± 0.9 nM, Bmax: 5922 ± 532 receptor/cells) and PAFR-G
q (Kd: 2.91 ± 0.3 nM, Bmax: 5721 ± 357 receptor/cells) bound the PAF antagonist WEB with pharmacological characteristics similar to those of the wild-type PAFR (Kd: 3.15 ± 1.3 nM, Bmax: 6144 ± 241 receptor/cells).
Functional characterization of PAFR-G
i3 and PAFR-G
q in RBL-2H3 cells
Upon activation by PAF, PAFR-G
i3, PAFR-G
q, and PAFR stimulated dose-dependent PI hydrolysis (Fig. 2A) and secretion of
-hexosaminidase (Fig. 2B) as well as time-dependent activation of intracellular Ca2+ mobilization (Fig. 2C) and GTPase activity in membranes (Fig. 2D). PAFR-G
q and PAFR-G
i3 induced greater GTPase activity (
0.17 pM of Pi/mg of protein) relative to PAFR (
0.12 pM of Pi/mg of protein) but mediated lower PI hydrolysis and secretion, and less sustained intracellular Ca2+ mobilization.
|
i3- and PAFR-G
q-mediated cellular responses in RBL-2H3 cells
We next determined the effect of Ptx on PAF-mediated receptor activation. As shown in Fig. 3, Ptx had no effect on PAFR-G
i3- or PAFR-G
q-mediated PI hydrolysis (Fig. 3A), secretion of
-hexosaminidase (Fig. 3B), and intracellular Ca2+ mobilization (data not shown). As expected, Ptx inhibited by
50% PAFR-induced PI hydrolysis and secretion of
-hexosaminidase (Fig. 3). The lack of inhibitory effect of Ptx on PAFR-G
i3-mediated responses likely suggests that the G
i3 attached to the C-tail of the receptor is resistant to ADP ribosylation. PAFR-G
i2 expressed in RBL-2H3 cells that mediated intracellular Ca2+ mobilization and PI hydrolysis to PAF as well as PAFR-G
i3 was also resistant to Ptx pretreatment (data not shown).
|
i3- and PAFR-G
q-mediated chemotaxis
The fusion receptors were also analyzed for their ability to mediate chemotaxis to PAF. PAFR-G
i3 and PAFR, but not PAFR-G
q, induced dose-dependent chemotaxis to PAF, with maximum response at
1 nm (Fig. 4A). PAFR-G
i3 showed a 3-fold increase in chemotaxis as compared with wild-type PAFR. Ptx has no significant effect on PAFR-G
i3-mediated chemotaxis but totally inhibited response to PAFR (Fig. 4B).
|
i3- and PAFR-G
q-mediated ERK activation
In vascular smooth muscle, PAF was shown to mediate cell migration via a MAPK-dependent pathway (31). To assess the ability of the fusion receptors to activate MAPK, we measured ERK1/2 phosphorylation in response to PAF. As shown in Fig. 5A, PAFR, PAFR-G
i3, and PAFR-G
q induced time-dependent phosphorylation of ERK1/2 in response to PAF (100 nM) stimulation. Maximum response was obtained at
1 min. PAFR induced ERK1/2 phosphorylation to a greater extent (
50%, Fig. 5B) relative to PAFR-G
i3 (
30%, Fig. 5C) or PAFR-G
q (
17%, Fig. 5D). PAFR-G
i3, however, showed a more sustained ERK1/2 phosphorylation as compared with PAFR (Fig. 5, B vs C).
|
i3 and PAFR-G
q in RBL-2H3 cells
RBL-2H3 cells expressing PAFR-G
i3, PAFR-G
q, or PAFR were labeled with 32P, treated with 100 nM PAF or PMA, and cell lysates were immunoprecipitated with HA Ab. As shown in Fig. 6A, PAFR (left panel;
42 kDa, monomer and
85 kDa, dimer; Refs. 19 and 32), PAFR-G
i3 (middle panel;
90 kDa), and PAFR-G
q (right panel;
95 kDa) were phosphorylated homologously by PAF (lanes 2) and heterologously by PMA (lanes 3) pretreatment. The specificity of the kinases was tested by measuring the effect of the protein kinase C inhibitor, staurosporine, on receptor phosphorylation. As previously shown (21), staurosporine (100 nM) had no effect on PAF-induced phosphorylation of PAFR (Fig. 6B, left panel, lanes 4 vs 3) but partially inhibited PMA-mediated phosphorylation (lanes 6 vs 5). In contrast, staurosporine totally inhibited PMA-mediated (lanes 6 vs 5), but partially PAF-mediated (lanes 4 vs 3), phosphorylation of PAFR-G
i3 (Fig. 6B, middle panel) and PAFR-G
q (Fig. 6B, right panel).
|
i3 and PAFR-G
q in RBL-2H3 cells
Intracellular Ca2+ mobilization in intact cells was measured to determine the susceptibility of the fusion receptors to desensitization. Cells were first exposed to PAF (1100 nM) and rechallenged 3 min later with a second dose of 1 µM. As shown in Fig. 7, AC, exposure of the cells to a first dose of PAF homologously desensitized response to a second dose, with an EC50 of 34 nM. Pretreatment with PMA (100 nM) also desensitized PAFR-, PAFR-G
i3-, and PAFR-G
q-mediated Ca2+ mobilization to PAF (Fig. 7D).
|
i3 (
56%), PAFR-G
q (
54%), and PAFR (
63%)-mediated GTPase activity in membranes (Fig. 7E). PMA (100 nM) pretreatment also inhibited PAFR-G
i3- (
45%), PAFR-G
q- (
52%), and PAFR- (
35%) mediated GTPase activity.
PAFR-G
i3 and PAFR-G
q mediated CXCR1 cross-desensitization in RBL-2H3 cells
Activation of the CXCL8 receptor CXCR1 was shown to cross-desensitize cellular responses to PAFR but not vice versa (23). To further determine the relationship between G protein usage and cross-desensitization, RBL-2H3 cells stably coexpressing CXCR1 along with PAFR (PAFR-CXCR1), PAFR-G
i3 (PAFR-G
i3-CXCR1), or PAFR-G
q (PAFR-G
q-CXCR1) were generated. CXCL8- and PAF-mediated cross-desensitization of Ca2+ mobilization was measured. As shown in Table I, pretreatment of PAFR-CXCR1 and PAFR-G
i3-CXCR1 cells with a first dose of CXCL8 (10 nM) cross-desensitized PAF-induced Ca2+ mobilization by 33 ± 7% and 42 ± 4%, respectively. PAFR-G
q (PAFR-G
q-CXCR1 cells) was resistant to cross-desensitization by CXCL8 (4 ± 3%). CXCR1-mediated Ca2+ mobilization was resistant to cross-desensitization by PAFR-G
q (PAFR-G
q-CXCR1 cells, 5 ± 9%) and PAFR (PAFR-CXCR1 cells, 6 ± 5%) but not PAFR-G
i3 (PAFR-G
i3-CXCR1 cells, 51 ± 11%).
|
i3 and PAFR-G
q in RBL-2H3 cells
PAF (100 nM) induced internalization of PAFR but not PAFR-G
i3 or PAFR-G
q (Fig. 8). PAFR was shown to internalize via a
arr-dependent mechanism. To determine whether the fusion receptors activate
arr, we transiently expressed a GFP-tagged
arr-1 in RBL cells expressing PAFR, PAFR-G
i3, or PAFR-G
q. Fluorescence microscopy was used to study the time course of PAF-mediated arrestin translocation and internalization. Upon exposure to PAF (100 nM), PAFR but not PAFR-G
i3 or PAFR-G
q induced translocation of
arr-1 to the cell membrane (Fig. 9).
|
|
| Discussion |
|---|
|
|
|---|
i3 and PAFR-G
q) to ensure specific receptor/G protein coupling to determine the role of Gi and Gq in PAF-induced signal transduction. This approach was previously used to study the efficacy of heterotrimeric G protein usage by different GPCRs such as the A1 adenosine receptor 1, the
-adrenoreceptor, the
-adrenoreceptor, and the chemoattractant FR (33, 34, 35, 36, 37, 38).
The data herein demonstrate that PAFR couples efficiently to both G
i and G
q to activate similar as well as different pathways. This contention is supported by the following observations. First, the fusion receptors and PAFR bind PAF to mediate PI hydrolysis, secretion, intracellular Ca2+ mobilization, ERK1/2 phosphorylation, and GTPase activity (Figs. 2, 3, and 5). In contrast, PAFR and PAFR-G
i3, but not PAFR-G
q, mediated chemotaxis in response to PAF (Fig. 4). In addition, PAFR-G
i3, but not PAFR or PAFR-G
q, cross-regulated Ca2+ response to CXCR1 (Table I).
Previous studies with G
-linked receptors have shown that the fusion does not alter the properties of either the G protein linked to the C terminus or the receptor (36, 37, 38, 39). The data herein also support these findings. The pharmacological properties of the fusion receptors (Kd: 1.48 ± 0.9 nM and 2.91 ± 0.3 nM for PAFR-G
i3 and PAFR-G
q, respectively) expressed in RBL-2H3 cells were similar to that of the wild-type PAFR (Kd: 3.15 ± 1.3 nM). PAFR-G
i3 and PAFR-G
q, however, mediated lower PI hydrolysis and exocytosis relative to PAFR (Figs. 2 and 3). Three possible explanations could account for this observation. First, maximal responses to PAFR are additive and as the wild-type receptor couples to both Gi and Gq, they may act synergistically to induce PI hydrolysis and secretion. Second, upon PAFR activation, both G
and G
are released to mediate leukocyte responses. In contrast, the PAFR-G protein fusion receptors could not release G
into the cytosol to activate PLC
. And, third, the fusion of the G
with the receptor promotes its deactivation and reassociation with G
, thereby, inhibiting receptor signaling. Supporting this contention is that both PAFR-G
i3 and PAFR-G
q mediated greater GTPase activity relative to PAFR (Fig. 2D). The
2AR-G
s fusion receptor was also shown to induce greater G protein activation but was less efficient in stimulating adenylate cyclase activity relative to wild-type
2AR (34).
PAFR-mediated PI hydrolysis and secretion are partially attenuated by Ptx (Fig. 3; Refs. 19 , 21 , 22). In the studies reported here, Ptx had no effect on PAFR-G
i3- and PAFR-G
q-mediated responses. Ptx was shown by others to inhibit cellular responses to the chemoattractant fusion receptor FR-G
i3 (39, 40). An explanation for the resistance of the PAFR-G
i3 to Ptx inhibition in our studies could be that the folding of the C terminus of the PAFR-G
i3 is different from that of the FR-G
i. Several GPCRs are palmitoylated on cysteine residues proximal to the cytosolic end of their seventh transmembrane to create a fourth intracellular loop (41). PAFR C-tail, but not FR, possesses several cysteine residues which are potential targets for palmitoylation (16, 42, 43, 44). Thus, it is possible that acylation of the PAFR-G
i3 C terminus upon activation anchors the G
i3-linked tail in the cellular membrane and hinders the access of the toxin to its cysteine target.
An interesting finding of this study is that PAFR-G
i3 mediated 3-fold greater chemotaxis relative to PAFR (Fig. 4). Furthermore, the PAFR-G
q, which stimulated greater GTPase activity than PAFR, did not mediate chemotaxis in response to PAF (Figs. 2 and 4). These results support previously published data suggesting that chemoattractant receptor-mediated cell motility requires G
released predominantly from G
i (22, 44). Thus, the increase in chemotactic activity by the PAFR-G
i3 fusion receptor likely indicates greater G
release from the G
i3-linked receptor relative to PAFR (Fig. 4). PAFR was also shown to mediate chemotaxis via a MAPK-dependent pathway stimulated by G
(31). Indeed, PAFR (
50%) and PAFR-G
i3 (
30%) induced greater ERK 1/2 phosphorylation than PAFR-G
q (
5%). Interestingly, PAFR-G
i3, which induced greater chemotaxis, mediated a more sustained ERK 1/2 phosphorylation relative PAFR (Fig. 5). These data support the role of MAPK in PAF-mediated chemotaxis, and indicate that the increase in chemotactic response to PAFR-G
i3 is likely due to the prolonged activation of the MAPK cascade.
A question addressed in this study was the role of G protein usage in PAFR regulation. Upon activation by PAF, PAFR was shown to undergo receptor phosphorylation and desensitization via two mechanisms: a G protein-coupled receptor kinase-dependent and a protein kinase C-dependent pathway (21, 45). As shown in Fig. 6, PAFR-G
i3 and PAFR-G
q underwent homologous and heterologous phosphorylation by both PAF and PMA. Furthermore, PAF and PMA pretreatment attenuated receptor-mediated GTPase activity in membrane and intracellular Ca2+ mobilization in intact cells (Fig. 7). These results suggest that the G
linked at the C-tail of the receptors did not perturb the access of the kinases to the phosphorylatable serine and threonine residues. FR-G
i was also shown to desensitize and internalize as well as the wild-type FR upon activation by fMLP (39, 40). In contrast to FR-G
i, however, PAFR-G
q and PAFR-G
i3 were resistant to internalization by PAF (Fig. 8). PAFR was previously shown to internalize in a phosphorylation/
arr-dependent fashion (21, 46). Deletion of the C terminus of PAFR, which prevented receptor phosphorylation and arrestin recruitment, inhibited receptor internalization (23). Because PAFR-G
q and PAFR-G
i3 undergo phosphorylation as well as PAFR, but failed to recruit arrestin (Figs. 6 and 9), this likely suggests that the presence of the G
subunits linked at the C-tail of the receptors prevented their association with
arr thereby inhibiting receptor internalization.
In summary, the data herein suggest that PAFR uses G
released from both Gi and Gq to activate similar as well as specific cellular responses. PAF-induced chemotactic and cross-regulatory signals are mediated exclusively via Gi coupling whereas cytotoxicity related functions are mediated by both Gi and Gq. PAFR-G
i3 mediated greater chemotaxis but was resistant to internalization. Thus, the data also suggest that receptor internalization is not required for PAFR-mediated leukocyte motility. Kelley et al. (47) recently demonstrated that GPCR could temporally activate different PLC isoforms to mediate acute and sustained responses. PAFR was shown to activate both PLC
2 and PLC
3 (48, 49). Does PAFR temporally couple to different G protein and PLC
isoforms to mediate chemotactic vs cytotoxic functions of leukocyte? Future studies using the fusion receptors described in this work will address this question.
| Acknowledgments |
|---|
arr plasmids, and Drs. Ralph Snyderman (Duke University) and Ifeanyi J. Arinze (Meharry Medical College) for critical reading of the manuscript. | Disclosures |
|---|
|
|
|---|
| Footnotes |
|---|
1 This work was supported by National Institutes of Health Grants AI-38910 (to R.M.R.) and AI-52381 (to B.H.). ![]()
2 Address correspondence and reprint requests to Dr. Ricardo M. Richardson, Julius L. Chambers Biomedical/Biotechnology Research Institute, North Carolina Central University, 1801 Fayetteville Street, Durham, NC 27707. E-mail address: mrrichardson{at}nccu.edu ![]()
3 Abbreviations used in this paper: PAF, platelet-activating factor; GPCR, G protein-coupled receptor; PLC, phospholipase C; Ptx, pertussis toxin; PI, phosphoinositide; FR, formylpeptide receptor; HA, hemagglutinin;
arr,
arrestin; IP, inositol phosphate. ![]()
Received for publication February 6, 2006. Accepted for publication June 2, 2006.
| References |
|---|
|
|
|---|
-adrenergic receptor function. FASEB J. 4: 2881-2889. [Abstract]
-arrestins in receptor signaling and desensitization. J. Biol. Chem. 273: 18677-18680.
-Arrestin/AP-2 interaction in G protein-coupled receptor internalization: identification of a
-arrestin binging site in
2-adaptin. J. Biol. Chem. 277: 9247-9254.
q leads to stimulation of src and focal adhesion kinase via two separate pathways in human umbilical vein endothelial cells. J. Biol. Chem. 279: 3497-3508.
-arrestin translocation and internalization of leukotriene B4 receptors. J. Biol. Chem. 280: 4880-4887.
B activation and Ca2+/calcineurin signaling pathways: inhibition by receptor phosphorylation and
-arrestin recruitment. J. Biol. Chem. 279: 44606-44612.
2A-adrenoceptor with multiple Gi-family G-proteins: studies with pertussis toxin-resistant G-protein mutants. Biochem. J. 321: 721-728. [Medline]
splice variants on
2-adrenoreceptor-mediated signaling: the
2-adrenoreceptor coupled to the long splice variant of Gs
has properties of a constitutively active receptor. J. Biol. Chem. 273: 5109-5116.
2-adrenoceptor-Gs
fusion protein. Eur. J. Biochem. 260: 661-666. [Medline]
2-adrenergic receptor/Gs interactions: evidence for multiple receptor conformations. Mol. Pharmacol. 56: 348-358.
G proteins following coexpression of receptor and G protein and expression of A1 adenosine receptor-Gi/o
fusion proteins. Biochemistry 38: 2272-2278. [Medline]
fusion protein following stable expression in CHO cells. FEBS Lett. 462: 61-65. [Medline]
1, Gi
2, and Gi
3. J. Biol. Chem. 274: 33259-33266.
i 2 fusion protein: assemblies with G proteins and arrestins. Biochemistry 42: 7283-7293. [Medline]
i is not required for chemotaxis mediated by Gi-coupled receptors. J. Biol. Chem. 274: 2824-2828.
and phospholipase C
3 in a temporally distinct manner. J. Biol. Chem. 281: 2639-2648.
3 phosphorylation in the desensitization of cellular responses to platelet-activating factor. J. Biol. Chem. 272: 11706-11709.
3 phosphorylation by protein kinase A. J. Biol. Chem. 273: 11012-11016. This article has been cited by other articles:
![]() |
M. W. Nasser, S. K. Raghuwanshi, D. J. Grant, V. R. Jala, K. Rajarathnam, and R. M. Richardson Differential Activation and Regulation of CXCR1 and CXCR2 by CXCL8 Monomer and Dimer J. Immunol., September 1, 2009; 183(5): 3425 - 3432. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Korhonen, B. Fisslthaler, A. Moers, A. Wirth, D. Habermehl, T. Wieland, G. Schutz, N. Wettschureck, I. Fleming, and S. Offermanns Anaphylactic shock depends on endothelial Gq/G11 J. Exp. Med., February 16, 2009; 206(2): 411 - 420. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Welch, R. P. Naikawadi, Z. Li, P. Lin, S. Ishii, T. Shimizu, C. Tiruppathi, X. Du, P. V. Subbaiah, and R. D. Ye Opposing Effects of Platelet-Activating Factor and Lyso-Platelet-Activating Factor on Neutrophil and Platelet Activation Mol. Pharmacol., January 1, 2009; 75(1): 227 - 234. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. J. D. McLaughlin, A. Banerjee, S. Y. Khan, J. L. Lieber, M. R. Kelher, F. Gamboni-Robertson, F. R. Sheppard, E. E. Moore, G. W. Mierau, D. J. Elzi, et al. Platelet-Activating Factor-Mediated Endosome Formation Causes Membrane Translocation of p67phox and p40phox That Requires Recruitment and Activation of p38 MAPK, Rab5a, and Phosphatidylinositol 3-Kinase in Human Neutrophils J. Immunol., June 15, 2008; 180(12): 8192 - 8203. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. W. Nasser, S. K. Raghuwanshi, K. M. Malloy, P. Gangavarapu, J.-Y. Shim, K. Rajarathnam, and R. M. Richardson CXCR1 and CXCR2 Activation and Regulation: ROLE OF ASPARTATE 199 OF THE SECOND EXTRACELLULAR LOOP OF CXCR2 IN CXCL8-MEDIATED RAPID RECEPTOR INTERNALIZATION J. Biol. Chem., March 2, 2007; 282(9): 6906 - 6915. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |